Cathie Wood Dumps Meta, Loads Up on Beaten-Down GeneDx Stock

TLDR

• Cathie Wood’s ARK Invest bought $15.88 million in GeneDx Holdings on January 12 after the stock fell 11.9% on disappointing guidance
• ARK purchased shares in Intellia Therapeutics, 10X Genomics, and Personalis while selling $13.29 million in Illumina stock
• Wood sold approximately $12.7 million in Meta Platforms shares across multiple ARK ETFs last week
• ARK added positions in Joby Aviation and Archer Aviation while trimming Roku and Palantir Technologies
• The trades show ARK moving away from established tech companies toward earlier-stage biotech and emerging innovation sectors

---

Cathie Wood’s ARK Invest made several major portfolio changes on January 12, with new regulatory filings showing the investment firm moving capital from mature tech stocks into earlier-stage biotech companies. The moves included both last week’s sales and Monday’s trading activity.

ARK’s biggest purchase was 133,191 shares of GeneDx Holdings for $15.88 million through the ARK Innovation ETF and ARK Genomic Revolution ETF. GeneDx operates as a global leader in rare disease diagnosis with the largest genomic dataset in that field. The purchase came after GeneDx shares dropped 11.9% on January 12 when the company released guidance that disappointed investors despite strong preliminary fiscal year 2025 results.

GeneDx Holdings Corp., WGS

Wood also bought 99,292 shares of Intellia Therapeutics for about $1.13 million. The clinical-stage biotech firm saw its stock price surge 10.2% on the same day. ARK added 49,963 shares of 10X Genomics after the stock declined 3.2%. Wood purchased 17,748 shares of Personalis, continuing a recent pattern of buying that stock.

On the selling side, Wood offloaded 91,312 shares of Illumina for $13.29 million. The sale suggests ARK is moving away from established genomics companies toward earlier-stage players. Illumina shares have risen nearly 48% over the past six months.

Meta and Tech Stock Sales

Last week, ARK sold approximately $12.7 million in Meta Platforms shares across the ARK Innovation ETF, ARKW, and ARKF funds. The sales reflect a broader move away from large-cap social media and mature tech companies.

ARK trimmed several other holdings on January 12. The firm sold $2.61 million in Natera shares and $5.15 million in Teradyne stock. Wood also reduced positions in Beam Therapeutics by $1.11 million and made a smaller sale in Ionis Pharmaceuticals.

While cutting established tech names, ARK added positions in advanced air mobility companies. The ARK Space Exploration & Innovation ETF bought shares of Joby Aviation and Archer Aviation. Both companies develop electric vertical takeoff and landing aircraft.

ARK also purchased Deere & Company stock, focusing on automation in construction and agriculture sectors. Other stocks trimmed last week included Roku and Palantir Technologies.

The trading pattern shows Wood moving capital from companies that have matured in the current market cycle toward emerging innovation sectors. ARK’s portfolio changes emphasize disruptive technologies in biotech, autonomous transport, and advanced manufacturing.

Wood’s biotech purchases focus on genomics and gene therapy companies at earlier development stages. The sales of Illumina and Meta represent exits from more established market leaders. ARK’s recent trades total more than $50 million in buy and sell transactions across multiple ETFs and sectors.

The post Cathie Wood Dumps Meta, Loads Up on Beaten-Down GeneDx Stock appeared first on CoinCentral.